source
- FDA sends warning letters to Sanofi and Viatris over misleading product claimsThe FDA’s Office of Prescription Drug Promotion issued untitled warning letters to Sanofi and Viatris after reviewing promotional materials that the agency deemed misleading. The letters cite spec…
- Summit Therapeutics' ivonescimab shows improved survival trend in extended follow-up, easing investor doubtsA new analysis of Summit Therapeutics and Akeso's dual‑acting cancer immunotherapy ivonescimab indicates that the drug's impact on overall survival has grown with longer observation. The extended d…